- Home
- AU vs TFX Comparison
AU vs TFX Comparison
Compare AU & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AU | TFX |
|---|---|---|
| Founded | 1944 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2B | 4.6B |
| IPO Year | 2023 | 1994 |
Fundamental Metrics
Financial Performance| Metric | AU | TFX |
|---|---|---|
| Price | $101.09 | $115.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $92.00 | ★ $138.75 |
| AVG Volume (30 Days) | ★ 2.9M | 666.3K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.51% | 1.18% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,992,713,000.00 |
| Revenue This Year | $35.44 | $15.97 |
| Revenue Next Year | N/A | $5.15 |
| P/E Ratio | $23.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.94 | $100.18 |
| 52 Week High | $129.14 | $138.93 |
Technical Indicators
Market Signals| Indicator | AU | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 52.79 | 55.97 |
| Support Level | $80.83 | $109.60 |
| Resistance Level | $115.81 | $123.74 |
| Average True Range (ATR) | 4.26 | 3.42 |
| MACD | 1.88 | 0.77 |
| Stochastic Oscillator | 82.46 | 72.55 |
Price Performance
Historical ComparisonAbout AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.